CSL Ltd. — Investor Presentation 2021

May 4, 2021

==> picture [205 x 32] intentionally omitted <==

==> picture [58 x 30] intentionally omitted <==

==> picture [262 x 27] intentionally omitted <==

For immediate release

5 May 2021

Presentation at Macquarie Australia Conference 2021

Please find attached a presentation to be given by Dr Paul McKenzie at the Macquarie Australia Conference 2021.

Authorised by Fiona Mead

Company Secretary

For further information, please contact:

Investors: Media: Bernard Ronchi Christina Hickie Senior Manager, Investor Relations Senior Manager, Communications CSL Limited CSL Limited T: +613 9389 3470 T: +613 9389 3425 M: +61 429 609 762 Email: bernard.ronchi@csl.com.au Email: christina.hickie@csl.com.au

==> picture [99 x 7] intentionally omitted <==

==> picture [101 x 89] intentionally omitted <==

CSL Limited Macquarie Conference 5 May, 2021

Paul McKenzie, PhD

Chief Operating Officer

FORWARD LOOKING STATEMENTS

Legal Notice

The materials in this presentation speak only as of the date of these materials and include forward looking statements about CSL Limited and its related bodies corporate (CSL) financial results and estimates, business prospects and products in research, all of which involve substantial risks and uncertainties, many of which are outside the control of, and are unknown to, CSL. You can identify these forward looking statements by the fact that they use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “target,” “may,” “assume,” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Factors that could cause actual results to differ materially include: the success of research and development activities, decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions or divestitures; research collaborations; litigation or government investigations, and CSL’s ability to protect its patents and other intellectual property. The statements being made in this presentation do not constitute an offer to sell, or solicitation of an offer to buy, any securities of CSL.

No representation, warranty or assurance (express or implied) is given or made in relation to any forward looking statement by any person (including CSL). In particular, no representation, warranty or assurance (express or implied) is given in relation to any underlying assumption or that any forward looking statement will be achieved. Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based.

Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, CSL disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change in events, conditions or circumstances on which any such statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of CSL since the date of these materials.

Trademarks

Except where otherwise noted, brand names designated by a ™ or ® throughout this presentation are trademarks either owned by and/or licensed to CSL.

2

Values and 2030 Strategy

==> picture [778 x 266] intentionally omitted <==

----- Start of picture text -----

• Technology
• Process Improvement
• Operational Excellence
• Capital Project Execution
• Products Growth Platforms:
• Delivery • Plasma
• Services • Recombinants
• Technology • Cell & Gene Therapy
Strategic • Influenza Vaccines
Overview
• Immunology
& Neurology • Connected
• Haematology Healthcare
& Thrombosis • New Capabilities
• Transplant
• Respiratory
• Cardiovascular
& Metabolic
• Influenza
----- End of picture text -----

Patient Innovation Integrity Focus Core Values We deliver on We turn innovative We walk the talk our promise thinking into to patients solutions

Superior Collaboration Performance We are stronger We take pride in together our results

3

Over the next decade, Operations has a critical role to play in helping CSL ensure that we can meet demand for our products and continue to deliver on our promise to patients and health systems.

==> picture [293 x 290] intentionally omitted <==

4

Changes in Operations have provided direction for new ways of working and behaviors required to achieve CSL’s 2030 Strategy

What We are Focused on Achieving

==> picture [40 x 39] intentionally omitted <==

Engaged and inclusive culture delivering top-tier results for safety, quality, reliability and innovation

==> picture [40 x 40] intentionally omitted <==

End-to-end operations visibility and control by partnering with the other key partners in delivering for our patients

==> picture [40 x 39] intentionally omitted <==

Global network mindset including both internal and external capabilities and ensure capacities to scalability

==> picture [40 x 40] intentionally omitted <==

An organization which embraces modernization to allow us to stabilize and scale

We have created a streamlined, de-layered, global Operations organization designed to scale and grow to deliver for our patients

==> picture [62 x 62] intentionally omitted <==

AN INTEGRATED, GLOBAL OPERATIONS NETWORK

==> picture [62 x 62] intentionally omitted <==

DECREASED LAYERS ACROSS THE NETWORK

==> picture [62 x 62] intentionally omitted <==

INTRODUCED NEW & EXPANDED CAPABILITIES

==> picture [62 x 61] intentionally omitted <==

ACCELERATED DIGITAL TRANSFORMATION

CONFIDENTIAL - Internal Use Only

Our Vision for Operations

“Operations enables CSL’s promise to patients and public health in the 2030 Strategy by developing a continuously learning team of CSL employees and partners that has a global mindset and is focused on efficiently delivering top-tier results for safety, quality, reliability and innovation.”

==> picture [846 x 241] intentionally omitted <==

----- Start of picture text -----

Safety Quality Reliability Innovation People
Establish an injury- Provide dono r- t o- Enhance our Become the most Be a continuously
free and patient quality that custome r- focused, agile responsive and learning organization
environmentally ensures we are always deman d- driven efficient E2E supply that embraces
responsible right first time and supply chain. chain, delivering diversity and inclusion
workplace driven by constantly inspectio n- profitable business and provides robust
individual ready. results. development
accountability and opportunities to our
behaviour. people to deliver on
our promise.
----- End of picture text -----

7

Operations Management of COVID-19 Challenges

• Plasma centers and manufacturing sites kept open during the pandemic to maintain supply of lifesaving medicines and influenza vaccines

• Took actions to prevent product and supply chain disruptions

• Development of strict protocols to ensure the safety of our employees and donors

• Provided support for COVID-19 vaccines and supply of MF59®

==> picture [268 x 179] intentionally omitted <==

==> picture [268 x 179] intentionally omitted <==

8

Plasma Collections

Continue to grow plasma collection network

==> picture [67 x 66] intentionally omitted <==

25 new centers opening in FY21 the United States

ALL CENTERS REMAIN OPEN

==> picture [76 x 76] intentionally omitted <==

300+ centers:

 284 United States

• 9 Germany

• 3 Hungary

• 5 China

==> picture [79 x 78] intentionally omitted <==

Plan to open 40 new centers in FY22

==> picture [202 x 178] intentionally omitted <==

9

Plasma Collections

COVID-19 Impact

==> picture [88 x 88] intentionally omitted <==

==> picture [82 x 82] intentionally omitted <==

Mitigation

Challenge

• Plasma collections adversely impacted

• Collection centers designated “essential critical infrastructure”

• FY20 plasma collection volume down

• Adjustments to U.S. donor compensation

• Call-back program for first-time, lapsed and temporarily deferred donors

• Additional collection costs incurred

• Comprehensive campaign to raise awareness of the opportunity and need for plasma donation

==> picture [88 x 88] intentionally omitted <==

Protecting Staff and Donors

Actions

• Pre-assessment of potential donors

• Plasma-designed social distancing

• Enhanced cleaning & disinfectant procedures

• ‘Safe passage’ letters provided to staff, donors and key vendors

10

Seqirus

==> picture [67 x 68] intentionally omitted <==

Operating Highlights

• Delivery of a record-setting >100 million doses for the Northern Hemisphere 20/21 influenza campaign

• Ongoing shift to differentiated products

• Real-world evidence continues to demonstrate the potential for improved effectiveness of FLUCELVAX[®] & FLUAD[®]

Looking Forward

• Planning underway for construction of new cell-culture vaccine facility in Melbourne

• Fill & finish expansion:

─ Liverpool operational from Northern Hemisphere 21/22

─ Holly Springs operational from Northern Hemisphere 22/23

==> picture [257 x 383] intentionally omitted <==

11

==> picture [101 x 89] intentionally omitted <==

Working for Patients & Human Health Around the World

==> picture [960 x 90] intentionally omitted <==